When you're responsible for the safety, efficacy, and stability of a pharmaceutical product, particulate matter presents a serious concern. For injectable formulations, unidentified particles can lead to toxicological effects, immune reactions, or physiological damage. For other products—creams, powders, emulsions— any change in particle size can alter chemical and physical behaviour, potentially compromising product performance, shelf life, and regulatory compliance.

Whether you’re conducting stability studies, final release testing, or root cause investigations, you need a partner with the breadth of equipment and the technical knowledge to identify, characterise, and quantify particles at every scale.

The Eurofins BioPharma Product Testing network of laboratories delivers comprehensive particulate matter testing services—covering both visible and subvisible particles—across a wide range of product and formulation issues—from protein aggregation through extraneous matter contamination. Our work is supported by a robust infrastructure of highly trained scientists, rigorous methodology, and globally compliant facilities.

This portfolio of methods enables accurate detection, sizing, and classification of particles in all forms—from solutions and suspensions to emulsions and lyophilised products.